This site is intended for UK Healthcare professionals only

Are you a UK Healthcare professional?

We are unfortunately unable to allow patients to attend DPC

We invite people living with diabetes to join our United Through Diabetes event happening on World Diabetes Day!

Join our World Diabetes Day event?

News

IMAGE

09 Jul 2021

Outcome of ABCD’s coronavirus and type 1 diabetes audit now available

Oliver Jelly

Critical symptoms of COVID-19 among patients in hospital with type 1 diabetes can be triggered by a greater BMI, microvascular problems and a weaker renal function.

The Association of British Clinical Diabetologists (ABCD) has revealed these results after nationally analysing the outcome of people with type 1 diabetes being admitted to hospital with coronavirus. 

The findings disclose that extreme COVID-19 cases are “reassuringly very low in people with type 1 diabetes who are under 55 years of age without microvascular or macrovascular disease”.

Over a six-month period in 2020, the audit explored the clinical traits of those with type 1 diabetes being admitted to hospital and the dangers linked to critical coronavirus cases.

The data was gathered from 40 centres across the UK, with 196 adults being included in the final dataset.  

The researchers said: “The prevalence of pre-existing microvascular disease and macrovascular disease was 56% and 39%, respectively. The prevalence of diabetic ketoacidosis on admission was 29%. A total of 68 patients (35%) died or were admitted to AICU.

“The proportions of people that died were 7%, 38% and 38% of those aged <55, 55–74 and ≥75 years, respectively. BMI, serum creatinine levels and having one or more microvascular complications were positively associated with the primary outcome after adjusting for age.”

They added: “In people with type 1 diabetes and COVID-19 who were admitted to hospital in the UK, higher BMI, poorer renal function and presence of microvascular complications were associated with greater risk of death and/or admission to AICU.

“Risk of severe COVID-19 is reassuringly very low in people with type 1 diabetes who are under 55 years of age without microvascular or macrovascular disease.”

To read the results, click here.

Additionally, a document defining how the ABCD gathered and interpreted the data is also available to access.

 

 

View all News
Loading

Sponsors

Diamond Sponsor

  • AstraZeneca

 

Platinum Sponsor

  • Novo Nordisk

 

Platinum Sponsor

  • Novo Nordisk

 

Platinum Sponsor

  • Abbott

 

Gold Sponsor

  • GlucoRX

 

Gold Sponsor

  • Roche

 

Gold Sponsor

  • Lilly

 

Gold Sponsor

  • BI Logo CMYK blue

 

Silver Sponsor

  • Duet

 

Silver Sponsor

  • Duet

 

Silver & Registration Sponsor

  • Diabetes Research & Wellness Foundation

 

Silver Sponsor

  • BD